0% commission for ETF trades
NASDAQ:AEZS
AEterna Zentaris Inc. Stock News
$5.72
+0 (+0%)
At Close: Sep 19, 2024
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.
06:00pm, Tuesday, 06'th Aug 2024
TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical com
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
04:05pm, Tuesday, 16'th Jul 2024
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing
Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the
Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders
03:18am, Friday, 07'th Jun 2024
MILWAUKEE , June 7, 2024 /PRNewswire/ -- Ademi LLP is investigating Aeterna (Nasdaq: AEZS) for possible breaches of fiduciary duty and other violations of law in its transaction with Ceapro. Click he
Aeterna Zentaris and Ceapro Complete Merger Transaction
09:15am, Monday, 03'rd Jun 2024
TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”)
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
06:35pm, Wednesday, 29'th May 2024
TORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercia
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
08:00am, Friday, 17'th May 2024
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has finalized certain details regarding the previo
Aeterna Zentaris Reports First Quarter 2024 Financial Results
06:00pm, Tuesday, 14'th May 2024
TORONTO, ONTARIO, May 14, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercia
Aeterna Zentaris Announces Effective Date of Share Consolidation
07:55am, Wednesday, 01'st May 2024
TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has filed articles of amendment to effect the prev
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
07:55am, Thursday, 28'th Mar 2024
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
10:26am, Wednesday, 27'th Mar 2024
Aeterna Zentaris (AEZS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $0.84 per share a year ago.
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
02:10pm, Tuesday, 12'th Mar 2024
TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to annou
TORONTO and EDMONTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovat
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") today announced that it has issued a Letter to Shareholders and Management Proxy Circular ahead
